ENDPOINTS

A unicorn stalks Wall Street in search of IPO cash; CASI Pharma in-licenses CD19 therapy from China’s Juventas

6 years ago

News Briefing

Newsmakers at #EHA19: Regeneron, ArQule track progress on response rates

6 years ago

R&D

AbbVie touts new data for Humira successor; Gilead inks discovery deal

6 years ago

News Briefing

Deerfield strikes up new deal with Columbia University; Ovid CEO Jeremy Levin joins BIO as new board chair

6 years ago

News Briefing

Celgene/Acceleron win speedy FDA review for luspatercept in beta thalassemia; Korean investor out to shake up ...

6 years ago

News Briefing

Novartis backs $30M round for cancer biotech; Bayer drug makes a ‘breakthrough’ at FDA

6 years ago

News Briefing

5 cash-hungry biotechs crowd into Nasdaq in search of a $600M-plus windfall

6 years ago

Financing

Akrevia scoops ex-Arsanis chief René Russo as CEO; Scott Gottlieb jumps back into industry; Seattle Genetics raids ...

7 years ago

Peer Review

IsoPlexis bags $25M to stoke T cell therapy buzz; Collaboration between X4 and LLS; New CMO at Precision Biosciences

7 years ago

News Briefing

Takeda forecasts $1.7B loss after Shire integration; Flagship's preclinical biotech Axcella closes IPO with $71M+ ...

7 years ago

News Briefing

BioNTech nabs PhI antibody and a new US base out of bankruptcy; Pfizer wins conditional drug OK

7 years ago

News Briefing

Confo Therapeutics raises €30 million; Waylivra receives approval from EU; endpoint met for Merck's Belsomra in ...

7 years ago

News Briefing

Esperion shares surge as FDA waves off panel review; Adaptimmune buoyed by a positive data snapshot

7 years ago

News Briefing

Peer Review: Anil Singhal assumes leadership of Adicet Bio; Adaptive Biotech woos Genentech vet as CMO

7 years ago

Peer Review

Celgene partners on Phase 0 cancer drug studies; FDA lifts clinical hold on Xencor's bispecific

7 years ago

News Briefing

Portola gets EU clearance to market Andexxa under new name; Four biotechs set terms for Nasdaq debut

7 years ago

News Briefing

Peer Review: KSQ woos Beni Wolf from Blueprint with CRISPR platform; AstraZeneca exec jumps to CNS biotech spun out ...

7 years ago

Peer Review

Four biotech Nasdaq wannabes outline IPO plans — and don't miss Chi-Med's HKEX pitch

7 years ago

Financing

WuXi AppTec recruits new CMO; Embattled Alkermes makes case for expanded use of schizophrenia drug Aristada

7 years ago

News Briefing

Rubius cites some preclinical progress; Xencor scores deal with Astellas; Eidos to restate quarterly filings

7 years ago

News Briefing

Three biotechs raise $100M+ in funding for gene therapies, cancer vaccines and more

7 years ago

News Briefing

Who are the women blazing trails in biopharma R&D? Nominate them for Endpoints' special report

7 years ago

Editor's note

Promedior makes a 'breakthrough' with PhIII IPF drug; NASH focused NGM Biopharma sets terms for IPO; bluebird bio ...

7 years ago

News Briefing

Roivant's rare disease shop captures FDA designations; China biotech lands $18M launch round

7 years ago

News Briefing

about the author

author articles

A unicorn stalks Wall Street in search of IPO cash; CASI Pharma in-licenses CD19 therapy from China’s Juventas

Newsmakers at #EHA19: Regeneron, ArQule track progress on response rates

AbbVie touts new data for Humira successor; Gilead inks discovery deal

Deerfield strikes up new deal with Columbia University; Ovid CEO Jeremy Levin joins BIO as new board chair

Celgene/Acceleron win speedy FDA review for luspatercept in beta thalassemia; Korean investor out to shake up ...

Novartis backs $30M round for cancer biotech; Bayer drug makes a ‘breakthrough’ at FDA

5 cash-hungry biotechs crowd into Nasdaq in search of a $600M-plus windfall

Akrevia scoops ex-Arsanis chief René Russo as CEO; Scott Gottlieb jumps back into industry; Seattle Genetics raids ...

IsoPlexis bags $25M to stoke T cell therapy buzz; Collaboration between X4 and LLS; New CMO at Precision Biosciences

Takeda forecasts $1.7B loss after Shire integration; Flagship's preclinical biotech Axcella closes IPO with $71M+ ...

BioNTech nabs PhI antibody and a new US base out of bankruptcy; Pfizer wins conditional drug OK

Confo Therapeutics raises €30 million; Waylivra receives approval from EU; endpoint met for Merck's Belsomra in ...

Esperion shares surge as FDA waves off panel review; Adaptimmune buoyed by a positive data snapshot

Peer Review: Anil Singhal assumes leadership of Adicet Bio; Adaptive Biotech woos Genentech vet as CMO

Celgene partners on Phase 0 cancer drug studies; FDA lifts clinical hold on Xencor's bispecific

Portola gets EU clearance to market Andexxa under new name; Four biotechs set terms for Nasdaq debut

Peer Review: KSQ woos Beni Wolf from Blueprint with CRISPR platform; AstraZeneca exec jumps to CNS biotech spun out ...

Four biotech Nasdaq wannabes outline IPO plans — and don't miss Chi-Med's HKEX pitch

WuXi AppTec recruits new CMO; Embattled Alkermes makes case for expanded use of schizophrenia drug Aristada

Rubius cites some preclinical progress; Xencor scores deal with Astellas; Eidos to restate quarterly filings

Three biotechs raise $100M+ in funding for gene therapies, cancer vaccines and more

Who are the women blazing trails in biopharma R&D? Nominate them for Endpoints' special report

Promedior makes a 'breakthrough' with PhIII IPF drug; NASH focused NGM Biopharma sets terms for IPO; bluebird bio ...

Roivant's rare disease shop captures FDA designations; China biotech lands $18M launch round